Barclays PLC Acquires 2,575 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

Barclays PLC lifted its holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 8.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 32,881 shares of the company’s stock after purchasing an additional 2,575 shares during the period. Barclays PLC’s holdings in Pulse Biosciences were worth $573,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. KLP Kapitalforvaltning AS purchased a new position in shares of Pulse Biosciences during the fourth quarter worth approximately $44,000. Caisse Des Depots ET Consignations purchased a new position in shares of Pulse Biosciences in the 4th quarter worth approximately $95,000. Farther Finance Advisors LLC raised its stake in shares of Pulse Biosciences by 44.4% during the 4th quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company’s stock worth $126,000 after acquiring an additional 2,220 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Pulse Biosciences during the fourth quarter valued at approximately $193,000. Finally, Wells Fargo & Company MN boosted its stake in Pulse Biosciences by 27.1% in the fourth quarter. Wells Fargo & Company MN now owns 11,315 shares of the company’s stock valued at $197,000 after acquiring an additional 2,416 shares in the last quarter. 76.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Monday, March 31st.

Pulse Biosciences Trading Up 1.0 %

Pulse Biosciences stock opened at $16.85 on Friday. Pulse Biosciences, Inc. has a one year low of $6.66 and a one year high of $25.00. The stock has a 50-day moving average of $16.66 and a two-hundred day moving average of $18.01.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Thursday, May 8th. The company reported ($0.25) EPS for the quarter.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.